Evaluation of the predictive value of CHA2DS2-VASc Score for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction who underwent Primary Percutaneous Coronary Intervention
Article Sidebar
Main Article Content
Abstract
Objective: The aim of this study was to estimate the predictive clinical value of CHA2DS2-VASc score for no-reflow phenomena in patients having ST-segment elevation myocardial infarction (STEMI) who applied to primary percutaneous coronary intervention (PCI).
Subjects and Methods: Three-hundred STEMI patients underwent primary PCI. They were classified into: group (1) included 27 patients with no-reflow and group (2) included 273 patients without no-reflow (control). CHA2DS2-VASc risk score was computed for each patient.
Results: This study found statistically significant difference (p < 0.05) in multivariate analysis of the association between CHA2DS2-VASc score and no-reflow phenomenon. The predictive power of individual components in CHA2DS2-VASc score for no-reflow was statistically significant difference (p < 0.05). So, significantly higher CHA2DS2-VASc score is connected with higher risk of no-reflow and in-hospital mortality rate.
Conclusion: Significantly higher CHA2DS2-VASc score is associated with higher risk of no- reflow phenomenon and in-hospital mortality rates in patients with STEMI who underwent primary PCI.
Article Details
Copyright (c) 2019 Abd El-Moneum MS.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Cardiology and Cardiovascular Medicine is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Cardiology and Cardiovascular Medicine is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58: 2550–2583. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22064601
Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008; 117: 3152–3156. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18559715
Durante A, Camici PG. Novel insights into an old phenomenon: the no reflow. Int J Cardiol. 2015; 187: 273–280. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25838230
Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008; 72: 950–957. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19021281
Mirbolouk F, Gholipour M, Salari A, Shakiba M, Kheyrkhah J, et al. CHA2DS2-VASc Score Predict No-Reflow Phenomenon in Primary Percutaneous Coronary Intervention in Primary Percutaneous Coronary Intervention. J Cardiovasc Thorac Res. 2018; 10: 46-52. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29707178
Ashoori A, Pourhosseini H, Ghodsi S, Salarifar M, Nematipour E, et al. CHA2DS2-VASc Score as an Independent Predictor of Suboptimal Reperfusion and Short-Term Mortality after Primary PCI in Patients with Acute ST Segment Elevation Myocardial Infarction. Medicina (Kaunas). 2019; 55: E35. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30717292
Bouleti C, Mewton N, Germain S. The no-reflow phenomenon: State of the art. Arch Cardiovasc Dis. 2015; 108: 661–674. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26616729
Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010; 137: 263–272. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19762550
Chan YH, Yiu KH, Lau KK, Lam TH, Lau CP, et al. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: role of incorporating PR prolongation. Atherosclerosis. 2014; 237: 504–513. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25463082
O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, et al. 2013 A CCF/AHA guideline for the management of ST–elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61: e78. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23247304
Rasoul S, Dambrink JH, Breeman A, Elvan A, van’t Hof AW. The relation between myocardial blush grade and myocardial contrast echocardiography: Which one is a better predictor of myocardial damage? Neth Heart J. 2010; 18: 25–30. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20111640
Carrick D, Oldroyd KG, McEntegart M, Haig C, Petrie MC, et al. A randomized trial of deferred stenting versus immediate stenting to prevent No- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). Am Coll Cardiol. 2014; 63: 2088–2098. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24583294
Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: Prospective multinational observational study (GRACE). BMJ. 2006; 333: 1091. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17032691
Bayramoğlu A, Taşolar H, Kaya A, Tanboğa İH, Yaman M, et al. Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients. J Interv Cardiol. 2018; 31: 144-149. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29193382
Magro M, Nauta ST, Simsek C, Boersma E, van der Heide E, et al. Usefulness of the SYNTAX Score to Predict “No Reflow” in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol. 2012; 109: 601–606. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22177003
Ipek G, Onuk T, Karatas MB, Gungor B, Osken A, et al. CHA2DS2-VASc Score is a Predictor of No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention. Angiology. 2015; 67: 840–845. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26685178
Bozbay M, Uyarel H, Cicek G, Oz A, Keskin M, et al. CHA2DS2-VASc Score Predicts In-Hospital and Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Who Were Undergoing Primary Percutaneous Coronary Intervention. Clin Appl Thromb Hemost. 2016; 23: 132–138. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27170782
Hioki H, Miura T, Miyashita Y, Motoki H, Shimada K, et al. Risk stratification using the CHA2DS2-VASc score in patients with coronary heart disease undergoing percutaneous coronary intervention; sub-analysis of SHINANO registry. IJC Heart Vasc. 2015; 7: 76–81. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28785649
Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010; 55: 2383–2389. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20488311
Harrison RW, Aggarwal A, Ou F, Klein LW, Rumsfeld JS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2012; 111: 178–184. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23111142
Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med. 2007; 357: 1631–1638. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17942875
Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003; 41: 1–7. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12570936
Dean J, Dela Cruz S, Mehta PK, Merz CNB. Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. Nat Rev Cardiol. 2015; 12: 406–414. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26011377
Kim J, Cha MJ, Lee DH, Lee HS, Nam CM, et al. The association between cerebral atherosclerosis and arterial stiffness in acute ischemic stroke. Atherosclerosis. 2011; 219: 887–891. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21974846
Heusch G. Cardioprotection: Chances and challenges of its translation to the clinic. Lancet. 2013; 381: 166–175. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23095318
Rezkalla SH, Stankowski RV, Hanna J, Kloner RA. Management of No-Reflow Phenomenon in the catheterization laboratory. J Am Coll Cardiolvasc Interv. 2017; 10: 215–223. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28183461
De Vita M, Burzotta F, Biondi-Zoccai GG, Lefevre T, Dudek D, et al. Individual patient-date meta-analysis comparing clinical outcome in patients with ST-elevation myocardial infarction treated with percutaneous Coronary intervention with or without prior thrombectomy. ATTEMPT study: A pooled Analysis of Trials on Thrombectomy in Acute Myocardial infarction based on individual Patient data. Vasc Health Risk Manag. 2009; 5: 243–247. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19436647
Chua SK, Lo HM, Chiu CZ, Shyu KG. Use of CHADS2 and CHA2DS2-VASc Scores to Predict Subsequent Myocardial Infarction, Stroke, and Death in Patients with Acute Coronary Syndrome: Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry. PLoS ONE. 2014; 9: e111167. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25343586
Al-Thani HA, El-Menyar A, Zubaid M, Rashed WA, Ridha M, et al. Peripheral arterial disease in patients presenting with acute coronary syndrome in six middle eastern countries. Int J Vasc Med. 2011; 2011: 815-902. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22220279